Stock RVV REVIVE THERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Revive Therapeutics Ltd.

Equities

RVV

CA7615161030

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange
Other stock markets
 01:23:32 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.03 CAD +20.00% Intraday chart for Revive Therapeutics Ltd. 0.00% 0.00%
Apr. 23 FDA Grants Revive Therapeutics Type C Meeting Request For Bucillamine Study to Treat Long COVID MT
Apr. 23 Revive Therapeutics Brief: Announcing Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID MT

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 11.67 6.879 54.93 187.3 147.5 16.09
Enterprise Value (EV) 1 10.61 6.404 53.91 171.1 143.9 14.23
P/E ratio -6.24 x -4.52 x -5.76 x -7.84 x -8.26 x -2.42 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -5.77 x -4.88 x -14.6 x -9.21 x -8.1 x -2.58 x
EV / FCF -12.2 x -9.26 x -30.3 x -31.7 x -21.7 x -3.34 x
FCF Yield -8.2% -10.8% -3.31% -3.16% -4.6% -29.9%
Price to Book 14.2 x 7.16 x 7.8 x 6.51 x 11.7 x 1.51 x
Nbr of stocks (in thousands) 58,351 72,411 189,409 317,409 320,678 357,647
Reference price 2 0.2000 0.0950 0.2900 0.5900 0.4600 0.0450
Announcement Date 10/26/18 10/24/19 10/28/20 10/25/21 10/28/22 10/27/23
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Giugno 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA 1 -1.84 -1.313 -3.685 -18.57 -17.78 -5.525
EBIT 1 -1.843 -1.317 -3.686 -18.57 -17.78 -5.525
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -1.791 -1.344 -5.382 -20.12 -17.81 -6.321
Net income 1 -1.791 -1.344 -5.382 -20.12 -17.81 -6.321
Net margin - - - - - -
EPS 2 -0.0321 -0.0210 -0.0504 -0.0752 -0.0557 -0.0186
Free Cash Flow 1 -0.8702 -0.6919 -1.782 -5.399 -6.617 -4.254
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 10/26/18 10/24/19 10/28/20 10/25/21 10/28/22 10/27/23
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1.06 0.48 1.02 16.2 3.59 1.87
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -0.87 -0.69 -1.78 -5.4 -6.62 -4.25
ROE (net income / shareholders' equity) -147% -151% -128% -111% -86% -54.4%
ROA (Net income/ Total Assets) -75.7% -68.5% -48.3% -61% -47.4% -22.1%
Assets 1 2.367 1.962 11.15 32.99 37.56 28.66
Book Value Per Share 2 0.0100 0.0100 0.0400 0.0900 0.0400 0.0300
Cash Flow per Share 2 0.0200 0.0100 0.0100 0.0500 0.0100 0.0100
Capex 1 0 - - - - -
Capex / Sales - - - - - -
Announcement Date 10/26/18 10/24/19 10/28/20 10/25/21 10/28/22 10/27/23
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
REVIVE THERAPEUTICS LTD. Stock Revive Therapeutics Ltd.
0.00% 9.17M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RVV Stock
  4. Financials Revive Therapeutics Ltd.